Zura Bio prices $125 million public offering at $6.25 per share

Zura Bio Limited (NASDAQ: ZURA) priced its public offering of 18,200,000 Class A ordinary shares at $6.25 per share and 1,800,000 pre-funded warrants at $6.249 each, according to a company statement. The clinical-stage biotechnology company expects to raise $125 million in gross proceeds before fees and expenses.

The offering includes an option for underwriters to purchase up to 3,000,000 additional shares within 30 days at the public offering price, minus underwriting discounts and commissions. The transaction is scheduled to close February 26, 2026, subject to standard closing conditions.

Leerink Partners, Piper Sandler and Cantor serve as joint bookrunning managers for the offering, with Wedbush PacGrow acting as lead manager. The securities are being offered through a shelf registration statement filed with the Securities and Exchange Commission in September 2024.

Henderson, Nevada-based Zura develops treatments for autoimmune and inflammatory diseases. The company's pipeline includes tibulizumab, currently in Phase 2 studies for hidradenitis suppurativa and systemic sclerosis, along with two other product candidates that have completed Phase 1 trials.

You May Also Be Interested In

• DEFSEC Technologies (DFSC) files for 4.05M share offering by selling stockholders
• Vox Royalty to acquire 2% gold royalty at White Dam for A$5M
• Lianhe Sowell prices $11M follow-on stock offering on Nasdaq